Pancreatic Carcinoma clinical trials

Explore recruiting pancreatic carcinoma clinical trials.

Recruiting pancreatic carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancreatic cancer

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer - ECT-LAPC Laparoscopic

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Poland, Italy, Netherlands, Sweden, Denmark, Finland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Pancreatic Cancer (Substudy PDAC)

France, Germany, Spain, Italy, Austria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II/III Randomized, Open-Label Clinical Study of Napabucasin in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients with Metastatic Pancreatic Cancer Following Chemotherapy Failure

France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Pancreatic Carcinoma trials by city

Pancreatic Carcinoma in Toronto Pancreatic Carcinoma in Vancouver Pancreatic Carcinoma in Montreal Pancreatic Carcinoma in Calgary Pancreatic Carcinoma in Edmonton Pancreatic Carcinoma in Ottawa Pancreatic Carcinoma in Winnipeg Pancreatic Carcinoma in Quebec City Pancreatic Carcinoma in Hamilton Pancreatic Carcinoma in Kitchener Pancreatic Carcinoma in London Pancreatic Carcinoma in Halifax Pancreatic Carcinoma in New York Pancreatic Carcinoma in Los Angeles Pancreatic Carcinoma in Chicago Pancreatic Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease